enGene Therapeutics Inc.ENGN
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing non-viral gene therapies using its proprietary enLIVE platform to deliver genetic medicines directly to target tissues. Its lead candidate, detalimogene voraplasmid, is in late-stage trials for high-risk non-muscle invasive bladder cancer, and the company is also advancing programs in other urological and ophthalmic indications. Investors track enGene for its differentiated delivery technology and the potential of its lead asset to address a significant unmet need in oncology.
Congressional Interest in enGene Therapeutics Inc. (ENGN)
No congressional trades have been disclosed for enGene Therapeutics Inc. (ENGN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading ENGN?
No congressional trades found for this stock.